BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. cell-cell adhesion, Inflammatory disorder, Embryo, Holistic medicine, Tamoxifen, EGFR)
Bookmark Forward

QuickView for c-MYC (gene)


Body Atlas

Most Correlated Tissues

  1. B lymphocyte (IgM memory) of spleen
  2. Vena cava
  3. Granulocyte-macrophage progenitor cell of bone marrow
  4. B lymphocyte (naive) of spleen
  5. Omental adipose tissue
Explore Body Atlas Results

Disease Atlas

Most Correlated Diseases

  1. Hyperoxia
  2. B-cell lymphoma
  3. Whipple's disease
  4. Physical activity
  5. Multiple organ dysfunction syndrome
Explore Disease Atlas Results

Pharmaco Atlas

Most Correlated Compounds

  1. CEP 14083
  2. microcystin RR
  3. FGF10 protein, human
  4. CGP 60474
  5. Quinacrine
Explore Pharmaco Atlas Results

Knockdown Atlas

Most Correlated Gene Perturbations

  1. MIR141
  2. KLF13
  3. MAP2K7
  4. PRKAR1B
  5. KAT5
Explore Knockdown Atlas Results

Curated Studies

Most Correlated Studies

Loading...
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Survey of activation-induced genome architecture reveals a novel enhancer of Myc.
  2. Rewired Metabolism Caused by the Oncogenic Deregulation of MYC as an Attractive Therapeutic Target i…
  3. MYC overexpression leads to increased chromatin interactions at super-enhancers and MYC binding site…
  4. Therapeutic targeting of "undruggable" MYC.
  5. Development and Characterization of Benzoselenazole Derivatives as Potent and Selective c-MYC Transc…
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma
  2. Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+…
  3. SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL W…
  4. Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma
  5. Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myelo…
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.